You are here

RayzeBio

Candid, with $370M, sets out to prove bispecifics’ worth in autoimmune disease

BioPharma Dive

Mon, 09/9/24 - 10:56 am

Candid Therapeutics

autoimmune disease

7 Billion-Dollar Oncology M&As from Q1

BioSpace

Wed, 04/10/24 - 11:24 am

Bristol Myers Squibb

Mirati Therapeutics

Fusion Pharmaceuticals

BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public

Fierce Biotech

Wed, 12/27/23 - 11:15 pm

Bristol Myers Squibb

radiopharmaceuticals

Biopharma’s top 5 IPOs of 2023 (so far)

Pharma Voice

Thu, 11/30/23 - 10:01 am

Apogee Therapeutics

Neumora Therapeutics

Mineralys Therapeutics

How biotech IPOs performed in the third quarter

BioPharma Dive

Tue, 10/3/23 - 10:28 am

Neumora Therapeutics

Mira Pharmaceuticals

Turnstone Biologics

Apogee Therapeutics

Sagimet Biosciences

60 Degrees Pharma

5 Life Sciences IPOs in 2023—and the Future Forecast

BioSpace

Wed, 09/20/23 - 08:51 am

Neumora Therapeutics

RayzeBio, Neumora price some of biotech’s largest IPOs this year

BioPharma Dive

Thu, 09/14/23 - 11:02 pm

Neumora Therapeutics

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Endpoints

Tue, 09/13/22 - 07:54 pm

radiopharmaceuticals

After Big Pharma sparked interest in the US, Ablaze looks to bring radiopharmaceuticals overseas

Endpoints

Tue, 11/30/21 - 10:26 am

Ablaze Pharmaceuticals

radiopharmaceuticals

Just shy of its 1-year anniversary, radiopharmaceuticals platform play RayzeBio bags another megaround

Endpoints

Tue, 06/15/21 - 10:43 am

radiopharmaceuticals

Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M

Endpoints

Tue, 12/8/20 - 10:52 am

radiopharmaceuticals